Ixiaro regulatory update

The World Health Organization (WHO) awarded prequalification to Biological E's Japanese Encephalitis (JE) vaccine for worldwide use in adults. Biological E expects WHO to extend the prequalification to include pediatric use by year end. The product is marketed as Ixiaro in Canada, Europe, Hong Kong, Israel, Singapore and the U.S., where it has Orphan Drug status, and as Jespect in Australia and New Zealand. ...